decitabine + homoharringtonine + cytarabine + aclarubicin + G-CSF

This is a five-drug combination chemotherapy regimen used primarily for the treatment of acute myeloid leukemia (AML), especially in elderly or high-risk patients. The regimen combines: - **Decitabine** (a hypomethylating agent that inhibits DNA methyltransferase, leading to reactivation of tumor suppressor genes and increased anti-tumor immunity) - **Homoharringtonine** (a plant alkaloid that inhibits protein synthesis and induces apoptosis in leukemia cells) - **Cytarabine** (an antimetabolite that inhibits DNA synthesis) - **Aclarubicin** (an anthracycline antibiotic with cytotoxic effects via intercalation into DNA and inhibition of topoisomerase II) - **G-CSF** (granulocyte colony-stimulating factor, which stimulates proliferation and differentiation of neutrophil precursors; used here as "priming" to enhance chemosensitivity) The combination is designed to maximize anti-leukemic efficacy by targeting multiple pathways involved in leukemogenesis while using G-CSF prim

Other names

HAAG regimenD-HAAGdecitabine plus HAAG